EICHOR
● Active Not Recruiting
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Condition: Lymphoma, Non-Hodgkin · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (11)
| Concord Hospital | Concord, Australia | — |
| St Vincents Hospital Melbourne | Fitzroy, Australia | — |
| Macquarie University Hospital | North Ryde, Australia | — |
| Hosp Univ Vall D Hebron | Barcelona, Spain | — |
| Hosp. Clinic de Barcelona | Barcelona, Spain | — |
| Inst. Cat. Doncologia-H Duran I Reynals | L'Hospitalet de Llobregat, Spain | — |
| Hosp. Gral. Univ. Gregorio Maranon | Madrid, Spain | — |
| Hosp. Univ. 12 de Octubre | Madrid, Spain | — |
| China Medical University Hospital | Taichung, Taiwan | — |
| National Taiwan University Hospital | Taipei, Taiwan | — |
| University Hospitals Of Leicester Nhs Trust | Leicester, United Kingdom | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06660563